BACKGROUND: Opioid maintenance treatment (OMT) has the potential to reduce mortality rates substantially. We aimed to compare all-cause and overdose mortality among OMT patients while in or out of OMT in two different countries with different approaches to OMT. METHODS: Two nation-wide, registry-based cohorts were linked by using similar analytical strategies. These included 3,637 male and 1,580 female patients enrolled in OMT in Czechia (years 2000-2019), and 6,387 male and 2,078 female patients enrolled in OMT in Denmark (years 2007-2018). The direct standardization method using the European (EU-27 plus EFTA 2011-2030) Standard was employed to calculate age-standardized rate to weight for age. All-cause and overdose crude mortality rates (CMR) as number of deaths per 1,000 person years (PY) in and out of OMT were calculated for all patients. CMRs were stratified by sex and OMT medication modality (methadone, buprenorphine, and buprenorphine with naloxone). RESULTS: Age-standardized rate for OMT patients in Czechia and Denmark was 9.7/1,000 PY and 29.8/1,000 PY, respectively. In Czechia, the all-cause CMR was 4.3/1,000 PY in treatment and 10.8/1,000 PY out of treatment. The overdose CMR was 0.5/1,000 PY in treatment and 1.2/1,000 PY out of treatment. In Denmark, the all-cause CMR was 26.6/1,000 PY in treatment and 28.2/1,000 PY out of treatment and the overdose CMR was 7.3/1,000 PY in treatment and 7.0/1,000 PY out of treatment. CONCLUSION: Country-specific differences in mortality while in and out of OMT in Czechia and Denmark may be partly explained by different patient characteristics and treatment systems in the two countries. The findings contribute to the public health debate about OMT management and may be of interest to practitioners, policy and decision makers when balancing the safety and accessibility of OMT.

1st Faculty of Medicine Department of Addictology Charles University Prague Czechia

Centre for Alcohol and Drug Research Aarhus University Aarhus Denmark

Department of Addictology General University Hospital Prague Prague Czechia

Norwegian Centre for Addiction Research University of Oslo Oslo Norway

Norwegian Institute of Public Health Oslo Norway

Zobrazit více v PubMed

Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. . Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies: mortality among opioid users. Addiction. (2011) 106:32–51. doi: 10.1111/j.1360-0443.2010.03140.x PubMed DOI

Vereinte Nationen B. für D. und V. (2018). World drug report 2018. Available at: https://www.unodc.org/wdr2018/

Compton WM, Jones CM. Epidemiology of the U.S. opioid crisis: the importance of the vector. Ann N Y Acad Sci. (2019) 1451:130–43. doi: 10.1111/nyas.14209 PubMed DOI PMC

Larney S, Tran LT, Leung J, Santo T, Santomauro D, Hickman M, et al. . All-cause and cause-specific mortality among people using Extramedical opioids: a systematic review and Meta-analysis. JAMA Psychiatry. (2020) 77:493. doi: 10.1001/jamapsychiatry.2019.4170 PubMed DOI PMC

Degenhardt L, Larney S, Randall D, Burns L, Hall W. Causes of death in a cohort treated for opioid dependence between 1985 and 2005: mortality among opioid-dependent people. Addiction. (2014) 109:90–9. doi: 10.1111/add.12337 PubMed DOI

World Health Organization, International Narcotics Control Board, and United Nations Office on Drugs and Crime . Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence World Health Organization; (2009). PubMed

European Monitoring Centre for Drugs and Drug Addiction . (2021). Balancing access to opioid substitution treatment with preventing the diversion of opioid substitution medications in Europe: challenges and implications. Publications Office. Available at: https://data.europa.eu/doi/10.2810/312876 DOI

Davoli M, Amato L, Clark N, Farrell M, Hickman M, Hill S, et al. . The role of Cochrane reviews in informing international guidelines: a case study of using the grading of recommendations, assessment, development and evaluation system to develop World Health Organization guidelines for the psychosocially assisted pharmac: Cochrane and GRADE for addiction guidelines. Addiction. (2015) 110:891–8. doi: 10.1111/add.12788 PubMed DOI

Tjagvad C, Skurtveit S, Linnet K, Andersen LV, Christoffersen DJ, Clausen T. Methadone-related overdose deaths in a Liberal opioid maintenance treatment Programme. Eur Addict Res. (2016) 22:249–58. doi: 10.1159/000446429 PubMed DOI

Kourounis G, Richards BDW, Kyprianou E, Symeonidou E, Malliori M-M, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. (2016) 161:1–8. doi: 10.1016/j.drugalcdep.2015.12.021 PubMed DOI

Santo T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. . Association of Opioid Agonist Treatment with all-Cause Mortality and Specific Causes of death among people with opioid dependence: a systematic review and Meta-analysis. JAMA Psychiatry. (2021) 78:979. doi: 10.1001/jamapsychiatry.2021.0976 PubMed DOI PMC

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. . Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. (2017) j1550. doi: 10.1136/bmj.j1550 PubMed DOI PMC

European Monitoring Centre for Drugs and Drug Addiction . (2017). Health and social responses to drug problems: a European guide. Publications Office. Available at: https://data.europa.eu/doi/10.2810/244934 DOI

European Monitoring Centre for Drugs and Drug Addiction . (2019). European drug report 2019: trends and developments. Publications Office. Available at: https://data.europa.eu/doi/10.2810/191370 DOI

Malinovská J, Mravčík V. Problem opioid use in the Czech Republic from a historical perspective: times are changing but opioid pharmaceuticals remain. Adiktologie. (2018) 18:215–22.

Thiesen H, Hesse M. Buprenorphine treatment in Denmark. Nordic Stud Alcohol Drugs. (2004) 21:152–5. doi: 10.1177/145507250402101s16 DOI

Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on Transmucosal and long-acting formulations. J Addict Med. (2019) 13:93–103. doi: 10.1097/ADM.0000000000000457 PubMed DOI PMC

Greenwald MK, Comer SD, Fiellin DA. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Drug Alcohol Depend. (2014) 144:1–11. doi: 10.1016/j.drugalcdep.2014.07.035 PubMed DOI PMC

Blazes CK, Morrow JD. Reconsidering the usefulness of adding naloxone to buprenorphine. Front Psych. (2020) 11:549272. doi: 10.3389/fpsyt.2020.549272 PubMed DOI PMC

Hickman M, Steer C, Tilling K, Lim AG, Marsden J, Millar T, et al. . The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom: burpenorphine vs methadone on mortality risk. Addiction. (2018) 113:1461–76. doi: 10.1111/add.14188 PubMed DOI PMC

Gabrhelík R, Handal M, Mravčík V, Nechanská B, Tjagvad C, Thylstrup B, et al. . Opioid maintenance treatment in the Czech Republic, Norway and Denmark: a study protocol of a comparative registry linkage study. BMJ Open. (2021) 11:e047028. doi: 10.1136/bmjopen-2020-047028 PubMed DOI PMC

Chomynová P, Grohmannová K, Dvořáková Z, Rous Z, Černíková T. Souhrnná zpráva o závislostech v České republice 2022 [Summary Report on Addictions in the Czech Republic in 2022]. Praha: Úřad vlády České republiky; (2023).

Hesse M, Thylstrup B, Seid AK, Tjagvad C, Clausen T. A retrospective cohort study of medication dispensing at pharmacies: administration matters! Drug Alcohol Depend. (2021) 225:108792. doi: 10.1016/j.drugalcdep.2021.108792 PubMed DOI

Ministerstvo zdravotnictví ČR . (2008). Věstník MZ ČR částka 3/2008—Standard substituční léčby [Journal of the Ministry of Health of the Czech Republic issue 3/2008—Standard of substitution treatment]. Available at: https://www.mzcr.cz/wp-content/uploads/wepub/2035/6204/Věstník%2003_2008.pdf

Mravčík V, Janíková B, Drbohlavová B, Popov P, Pirona A. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic. Harm Reduct J. (2018) 15:1. doi: 10.1186/s12954-018-0268-0 PubMed DOI PMC

Frank VA, Bjerge B, Houborg E. Shifts in opioid substitution treatment policy in Denmark from 2000–2011. Subst Use Misuse. (2013) 48:997–1009. doi: 10.3109/10826084.2013.797838 PubMed DOI

Bjerge B, Nielsen B, Frank VA. Rationalities of choice and practices of care: substitution treatment in Denmark. Contemp Drug Probl. (2014) 41:57–90. doi: 10.1177/009145091404100104 DOI

Sundhedsstyrelsen [The Danish Board of Health] . Evaluering af ordning med lægeordineret heroin til stofmisbrugere 2010–2012 [Evaluation of pharmaceutical heroin for people with opioid addiction 2010-2012]. Denmark:Copenhagen. (2013).

Thylstrup B., Schrøder S., Pedersen MM., Ludvigsen KB. Brugernes tilfredshed med substitutionsbehandlingen [Patients’ satisfaction with Substitution Treatment]. Socialministeriet [The Ministry of Social Services], Denmark:Copenhagen. (2015).

Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. (2011) 39:26–9. doi: 10.1177/1403494811399958 PubMed DOI

Bukten A, Skurtveit S, Waal H, Clausen T. Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study. Addict Behav. (2014) 39:1504–9. doi: 10.1016/j.addbeh.2014.05.007 PubMed DOI

European Monitoring Centre for Drugs and Drug Addiction . (2009). Standard protocol version 3.2 for the EU Member States to collect data and report figures for the Key indicator drug-related deaths. Lisbon, European Monitoring Centre for Drugs and Drug Addiction. Available at: https://www.emcdda.europa.eu/system/files/publications/615/DRD_Standard_Protocol_version_3.2_216365.pdf

European Commission . Eurostat. (2013). Revision of the European standard population: Report of Eurostat’s task force: 2013th edition. Publications Office. Available at: https://data.europa.eu/doi/10.2785/11470 DOI

IBM Corp . IBM SPSS statistics for windows, version 24.0. Armonk, NY: IBM Corp; (2016).

StataCorp . Stata statistical software: Release 16. College Station, TX: StataCorp LLC; (2019).

Bukten A, Stavseth MR, Clasuen T. From restrictive to more liberal: variations in mortality among patients in opioid maintenance treatment over a 12-year period. BMC Health Serv Res. (2019) 19:553. doi: 10.1186/s12913-019-4382-9 PubMed DOI PMC

Kim HK, Nelson LS. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf. (2015) 14:1137–46. doi: 10.1517/14740338.2015.1037274 PubMed DOI

McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. (2016) 111:1177–87. doi: 10.1111/add.13326 PubMed DOI PMC

Moustaqim-Barrette A, Dhillon D, Ng J, Sundvick K, Ali F, Elton-Marshall T, et al. . Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review. BMC Public Health. (2021) 21:597. doi: 10.1186/s12889-021-10497-2 PubMed DOI PMC

Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med. (1966) 118:304–9. PubMed

Gabrhelík R, Skurtveit S, Nechanská B, Handal M, Mahic M, Mravčík V. Prenatal methamphetamine exposure and adverse neonatal outcomes: a Nationwide cohort study. Eur Addict Res. (2020) 27:97–106. doi: 10.1159/000509048 PubMed DOI

Mravčík V, Nechanská B, Gabrhelík R, Handal M, Mahic M, Skurtveit S. Socioeconomic characteristics of women with substance use disorder during pregnancy and neonatal outcomes in their newborns: a national registry study from the Czech Republic. Drug Alcohol Depend. (2020) 209:107933. doi: 10.1016/j.drugalcdep.2020.107933 PubMed DOI